Ozempic 0.25mg appetite and bloating claims: what the data says

What's this video probably claiming?

Based on the caption, this creator is documenting early-stage semaglutide use at the 0.25mg starting dose, describing near-total appetite suppression in the morning and significant bloating after attempting to eat. She also notes that appetite returns somewhat in the evenings, a few days after her weekly injection. This is a common format on GLP-1 TikTok: the personal food diary framed as a side-effect log. At 77,000 views, it's reaching a meaningful audience who may be starting or considering Ozempic themselves. The implicit message is that zero appetite is normal, even expected, at this dose, and that meal timing around injection day matters. Neither of these claims is wrong exactly, but the framing collapses a lot of individual variation into a single experience that viewers may treat as a template.

What does the science actually show?

Nausea and appetite suppression are the most consistently reported early side effects of semaglutide, and the published trial data backs this up. In the STEP 1 trial (Wilding et al., 2021, New England Journal of Medicine), 44.2% of participants in the semaglutide 2.4mg group reported nausea, with rates highest during dose escalation. Gastrointestinal symptoms including bloating, nausea, and early satiety are dose-dependent and most pronounced in the first 4 to 8 weeks. At the 0.25mg dose specifically, which is a sub-therapeutic starting dose used purely for tolerability, appetite suppression is already measurable. A 2023 pharmacokinetic analysis published in Clinical Pharmacokinetics confirmed that semaglutide reaches steady-state plasma concentrations after roughly 4 to 5 weeks at any given dose, which explains why symptom patterns shift over the weekly injection cycle. The appetite-in-evenings pattern she describes is biologically plausible: peak plasma concentrations occur 1 to 3 days post-injection, and GI side effects tend to cluster around that window.

Where does the social media noise diverge from clinical reality?

The bigger problem with this genre of content is not what it says but what it normalises by omission. Eating almost nothing and pushing through bloating gets framed as progress. That's a potentially harmful signal for a large audience. Clinically, not eating enough while on semaglutide is associated with lean mass loss, not just fat loss. A 2022 analysis by Rubino et al. in Obesity (the STEP 4 trial extension data) showed that without adequate protein intake, GLP-1 users can lose disproportionate muscle mass. There is also no discussion here of whether this creator is under medical supervision, has had a dietary briefing, or is tracking nutritional adequacy. The hashtag includes both ozempicuk and semiglutide (misspelled), alongside monjaro (also misspelled, presumably Mounjaro/tirzepatide), which suggests the creator may be conflating different drug classes in her wider content. Tirzepatide and semaglutide are not interchangeable, and their side-effect profiles differ in measurable ways.

What should you actually know?

If you are starting semaglutide at 0.25mg and experiencing appetite suppression and bloating, you are having a textbook early response to the drug. That does not mean you should skip meals. GLP-1 receptor agonists slow gastric emptying, which is partly why you feel full fast and bloated after eating, but the clinical guidance from prescribers trained in this area is consistent: prioritise protein, eat smaller portions more frequently, and do not treat appetite suppression as permission to under-eat. The STEP trials used dietary and exercise counselling alongside the medication, not just the injection alone. If your appetite is genuinely this suppressed on 0.25mg, that is worth flagging to whoever is prescribing your medication, not just documenting for TikTok. Symptom diaries are not a substitute for clinical monitoring, especially when you are on a drug that affects nutrient absorption timing and lean mass retention over months of use.